Protein Hydrolysate Therapy

Reports from Tianjin University add new data to research in protein hydrolysate therapy

Published in Pharma Law Weekly, December 29th, 2009

"The antitumor and antioxidative activities of a rapeseed protein hydrolysate (RSCH) obtained from rapeseed meal were evaluated by using an in vivo S180 tumor-bearing Kunming mice model. Tumor-bearing female mice were given RSCH for 10 at doses of 0, 50, 100, and 150 mg/kg/d by gastric perfusion," researchers in Tianjin, People's Republic of China report.

"RSCH significantly decreased the tumor weight by 44% and 53% in the 100 and 150 mg/kg/d groups, respectively, without causing mortality or growth retardation. The thymus and spleen indices (organ weight relative to body weight) were increased significantly in the 150 mg/kg/d group. The phagocytic capability of coeliac...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2009-12-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry